These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 24333704)

  • 1. Development and validation of an indirect pulsed electrochemical detection method for monitoring the inhibition of Abl1 tyrosine kinase.
    Chen H; Wang X; Chopra S; Adams E; Van Schepdael A
    J Pharm Biomed Anal; 2014 Mar; 90():52-7. PubMed ID: 24333704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of Abl1 tyrosine kinase inhibitors by liquid chromatography-electrospray ionization-mass spectrometry.
    Chen H; Adams E; Van Schepdael A
    Talanta; 2013 Mar; 107():88-94. PubMed ID: 23598197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Electrochemical evaluation of Abelson tyrosine-protein kinase 1 activity and inhibition by imatinib mesylate and danusertib.
    Diculescu VC; Enache TA
    Anal Chim Acta; 2014 Oct; 845():23-9. PubMed ID: 25201268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib.
    Ernst T; Gruber FX; Pelz-Ackermann O; Maier J; Pfirrmann M; Müller MC; Mikkola I; Porkka K; Niederwieser D; Hochhaus A; Lange T
    Haematologica; 2009 Sep; 94(9):1227-35. PubMed ID: 19608684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The synthesis of Bcr-Abl inhibiting anticancer pharmaceutical agents imatinib, nilotinib and dasatinib.
    Deadman BJ; Hopkin MD; Baxendale IR; Ley SV
    Org Biomol Chem; 2013 Mar; 11(11):1766-800. PubMed ID: 23247657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma.
    De Francia S; D'Avolio A; De Martino F; Pirro E; Baietto L; Siccardi M; Simiele M; Racca S; Saglio G; Di Carlo F; Di Perri G
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Jun; 877(18-19):1721-6. PubMed ID: 19428316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia.
    Eiring AM; Page BDG; Kraft IL; Mason CC; Vellore NA; Resetca D; Zabriskie MS; Zhang TY; Khorashad JS; Engar AJ; Reynolds KR; Anderson DJ; Senina A; Pomicter AD; Arpin CC; Ahmad S; Heaton WL; Tantravahi SK; Todic A; Moriggl R; Wilson DJ; Baron R; O'Hare T; Gunning PT; Deininger MW
    Leukemia; 2015 Mar; 29(3):586-597. PubMed ID: 25134459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors.
    Corbin AS; O'Hare T; Gu Z; Kraft IL; Eiring AM; Khorashad JS; Pomicter AD; Zhang TY; Eide CA; Manley PW; Cortes JE; Druker BJ; Deininger MW
    Cancer Res; 2013 Sep; 73(18):5775-86. PubMed ID: 23887971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC).
    D'Avolio A; Simiele M; De Francia S; Ariaudo A; Baietto L; Cusato J; Fava C; Saglio G; Di Carlo F; Di Perri G
    J Pharm Biomed Anal; 2012 Feb; 59():109-16. PubMed ID: 22036594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib.
    Olshen A; Tang M; Cortes J; Gonen M; Hughes T; Branford S; Quintás-Cardama A; Michor F
    Haematologica; 2014 Nov; 99(11):1701-9. PubMed ID: 25216683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients.
    Pirro E; De Francia S; De Martino F; Fava C; Ulisciani S; Cambrin GR; Racca S; Saglio G; Di Carlo F
    J Chromatogr Sci; 2011; 49(10):753-7. PubMed ID: 22080802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BCR-ABL1 transcript at 3 months predicts long-term outcomes following second generation tyrosine kinase inhibitor therapy in the patients with chronic myeloid leukaemia in chronic phase who failed Imatinib.
    Kim DD; Lee H; Kamel-Reid S; Lipton JH
    Br J Haematol; 2013 Mar; 160(5):630-9. PubMed ID: 23278256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of twelve nucleotides insertion in the BCR-ABL kinase domain in an imatinib-resistant but dasatinib-sensitive patient with bi-phenotypic acute leukemia.
    Hayette S; Chabane K; Tchirkov A; Berger MG; Nicolini FE; Tournilhac O
    Haematologica; 2009 Sep; 94(9):1324-6. PubMed ID: 19734429
    [No Abstract]   [Full Text] [Related]  

  • 14. Simultaneous measurement of imatinib, nilotinib and dasatinib in dried blood spot by ultra high performance liquid chromatography tandem mass spectrometry.
    Kralj E; Trontelj J; Pajič T; Kristl A
    J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Aug; 903():150-6. PubMed ID: 22857863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous Determination of Imatinib, Dasatinib, and Nilotinib by Liquid Chromatography-Tandem Mass Spectrometry and Its Application to Therapeutic Drug Monitoring.
    Wojnicz A; Colom-Fernández B; Steegmann JL; Muñoz-Calleja C; Abad-Santos F; Ruiz-Nuño A
    Ther Drug Monit; 2017 Jun; 39(3):252-262. PubMed ID: 28490048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.
    Soverini S; Gnani A; Colarossi S; Castagnetti F; Abruzzese E; Paolini S; Merante S; Orlandi E; de Matteis S; Gozzini A; Iacobucci I; Palandri F; Gugliotta G; Papayannidis C; Poerio A; Amabile M; Cilloni D; Rosti G; Baccarani M; Martinelli G
    Blood; 2009 Sep; 114(10):2168-71. PubMed ID: 19589924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance.
    Quentmeier H; Eberth S; Romani J; Zaborski M; Drexler HG
    J Hematol Oncol; 2011 Feb; 4():6. PubMed ID: 21299849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib.
    Shah NP; Kim DW; Kantarjian H; Rousselot P; Llacer PE; Enrico A; Vela-Ojeda J; Silver RT; Khoury HJ; Müller MC; Lambert A; Matloub Y; Hochhaus A
    Haematologica; 2010 Feb; 95(2):232-40. PubMed ID: 20139391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dasatinib: is it all in the dose?
    Condorelli F; Genazzani AA
    BioDrugs; 2010 Jun; 24(3):157-63. PubMed ID: 20222756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apoptosis in chronic myeloid leukemia cells transiently treated with imatinib or dasatinib is caused by residual BCR-ABL kinase inhibition.
    Simara P; Stejskal S; Koutna I; Potesil D; Tesarova L; Potesilova M; Zdrahal Z; Mayer J
    Am J Hematol; 2013 May; 88(5):385-93. PubMed ID: 23420553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.